RESUMO
Tests that positively identify individuals with ulcerative colitis, distinguishing them from patients with Crohn disease or other causes of colitis, have not been reliable. Genetic predisposition to inflammatory bowel diseases and genetic influence on immune regulation resulted in the clinical evaluation of potential serologic markers. In adults the presence of anti-neutrophil cytoplasmic antibody (ANCA) in serum identifies patients with ulcerative colitis. In this study we demonstrated that high levels of ANCA are present in 83% of children and adolescents with ulcerative colitis. Furthermore, the majority of patients with ulcerative colitis had a perinuclear pattern of these antibodies by indirect immunofluorescence. The combination of a positive ANCA and perinuclear indirect immunofluorescence pattern was 97% specific for ulcerative colitis. We conclude that determination of ANCA is a sensitive and specific clinical test for identification of children and adolescents with ulcerative colitis.
Assuntos
Autoanticorpos/imunologia , Colite Ulcerativa/sangue , Doença de Crohn/sangue , Citoplasma/imunologia , Imunoglobulina G/imunologia , Neutrófilos/imunologia , Adolescente , Adulto , Fatores Etários , Análise de Variância , Autoanticorpos/metabolismo , Biomarcadores/sangue , Estudos de Casos e Controles , Criança , Pré-Escolar , Colectomia , Colite Ulcerativa/complicações , Colite Ulcerativa/imunologia , Colite Ulcerativa/cirurgia , Doença de Crohn/complicações , Doença de Crohn/imunologia , Doença de Crohn/cirurgia , Citoplasma/metabolismo , Ensaio de Imunoadsorção Enzimática , Fluorimunoensaio , Hemorragia Gastrointestinal/sangue , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/imunologia , Humanos , Imunoglobulina G/metabolismo , Lactente , Recém-Nascido , Neutrófilos/metabolismo , Ligação Proteica , Sensibilidade e EspecificidadeRESUMO
Because pancreatitis has been reported frequently in adults with human immunodeficiency virus infection, we sought to determine the incidence of pancreatitis in children with acquired immunodeficiency syndrome by reviewing all records of children with AIDS, their serum amylase and lipase levels, and the factors associated with pancreatitis through a case-control analysis. During a 6-year period pancreatitis developed in 9 (17%) of 53 pediatric patients with AIDS. Six children had vertical transmission of infection and three patients had acquired HIV infection through contaminated blood products. Pancreatitis developed at a median age of 5.2 years (range 1.2 to 20 years). All patients had vomiting and abdominal pain. When the patients were first seen, lipase values were elevated more than amylase values (p = 0.028). Amylase and lipase levels declined at comparable rates. In the case-control analysis, pentamidine isethionate was significantly associated with pancreatitis (p = 0.02); the risk was greater in patients who received pentamidine isethionate and had absolute CD4 T-lymphocyte counts less than 100 cells/mm3 (p = 0.001). Infections associated with the onset of pancreatitis included cytomegalovirus (4), Cryptosporidium (1), Pneumocystis carinii pneumonia (3), and Mycobacterium avium intracellulare (1). Coinfection with cytomegalovirus was associated with a protracted course in four children. Ultrasonographic examination demonstrated biliary ductal dilatation 6 months after the onset of pancreatitis in one child. Seven children have died at a mean of 8 months after the initial onset of pancreatitis; the one living child has survived 5 months from the onset of pancreatitis. We conclude that pancreatitis is common in pediatric patients with AIDS and may be related to pentamidine isethionate exposure, especially when absolute CD4 T-lymphocyte counts are less than 100 cells/mm3. Serum amylase levels do not always accurately predict the onset of pancreatitis; serum lipase levels should be measured in children with symptoms. The onset of pancreatitis in an HIV-infected child is a poor prognostic indicator.
Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Pancreatite/complicações , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/imunologia , Adolescente , Adulto , Amilases/sangue , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Lipase/sangue , Masculino , Infecções Oportunistas/complicações , Pancreatite/enzimologia , Subpopulações de Linfócitos TRESUMO
We describe a child with circulating anti-epithelial cell antibodies, autoimmune enteropathy with intestinal villous atrophy, and membranous glomerulonephritis. The patient had persistent diarrhea at 6 months of age, and a small bowel biopsy showed active enteritis, villous atrophy, and crypt hyperplasia. When the patient was, 10 months of age, nephrotic syndrome developed because of membranous glomerulonephritis. Results of tests for circulating immune complexes were negative. Indirect immunofluorescence studies revealed a circulating antibody directed against renal epithelial cells. Circulating antibodies directed against normal small intestine epithelial cells were also detected by the immunoperoxidase technique. Western blot and immunoprecipitation identified a 55-kd antigen, in both small bowel and kidney, that reacted with an antibody in the patient's serum. High-dose prednisone therapy induced a clinical remission, resolution of the small bowel injury, and diminished serum anti-epithelial cell antibodies; after dose reduction, clinical relapse occurred with villous atrophy and reappearance of anti-epithelial cell antibodies. When the patient was 45 months of age, persistent diarrhea recurred despite intravenous administration of corticosteroids, cyclosporine, and total parenteral nutrition. Autoantibodies to a 55-kd epithelial cell protein are temporally related to the development of enteropathy and nephropathy. Study of similar patients is needed to determine the role of such antibodies in this disorder.
Assuntos
Autoanticorpos/sangue , Doenças Autoimunes/imunologia , Glomerulonefrite Membranosa/imunologia , Enteropatias/imunologia , Intestino Delgado/patologia , Atrofia , Doenças Autoimunes/sangue , Doenças Autoimunes/tratamento farmacológico , Células Epiteliais , Epitélio/imunologia , Glomerulonefrite Membranosa/sangue , Glomerulonefrite Membranosa/tratamento farmacológico , Humanos , Imunoglobulinas/análise , Lactente , Enteropatias/sangue , Enteropatias/tratamento farmacológico , Intestino Delgado/imunologia , Masculino , Prednisona/uso terapêuticoRESUMO
During a 6-year period, we treated 21 patients with azathioprine, 2 mg/kg/day, as an adjunct to their customary regimen. Nine patients had ulcerative colitis and 12 patients had Crohn disease; the patients' ages ranged from 3 to 17 years. The median duration of disease before the start of azathioprine therapy was 2 years, and median follow-up was 2 years. Sixteen patients seemed to respond to azathioprine therapy: six patients in each disease group had complete responses and four patients (one with ulcerative colitis and three with Crohn disease) had partial responses. Two patients with ulcerative colitis and three patients with Crohn disease did not respond. The median time until patients responded was less than 3 months for patients with ulcerative colitis and 4 months for those with Crohn disease. Reduction of corticosteroid dose was possible for all patients who responded to azathioprine therapy. Only minimal side effects were attributable to the drug. We conclude that azathioprine is an effective adjunctive agent for the treatment of inflammatory bowel disease in childhood, but because questions remain regarding its long-term safety, its use should be reserved for children with refractory disease or severe and unacceptable side effects of corticosteroids.
Assuntos
Azatioprina/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Administração Oral , Adolescente , Corticosteroides/uso terapêutico , Azatioprina/administração & dosagem , Azatioprina/efeitos adversos , Criança , Pré-Escolar , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Avaliação de Medicamentos , Feminino , Seguimentos , Humanos , Masculino , Fatores de TempoRESUMO
Controversy exists regarding the value of gross mucosal changes of the esophagus at the time of endoscopy in predicting histologic esophagitis. Accordingly, we reviewed the records of 279 pediatric patients who underwent both an upper endoscopy and simultaneous grasp esophageal biopsy. Of those patients with no gross mucosal abnormalities, 30% had evidence of esophagitis on biopsy. Similarly, there was a poor association between the presence of endoscopic findings and histologic esophagitis. We conclude that gross esophageal mucosal changes are poor predictors of histologic esophagitis and that endoscopic evaluation alone is inadequate for children and adolescents in whom esophagitis is suspected. Esophageal biopsies should be obtained in all such patients, even when no gross mucosal abnormalities are found.